Cancer Letters
Volume 291, Issue 1 , Pages 90-98 , 1 May 2010

Downregulation of nuclear factor-κB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer

  • Rui Kong

      Affiliations

    • The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
    • ,
  • Bei Sun

      Affiliations

    • The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
    • Corresponding Author InformationCorresponding authors. Address: The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China. Tel.: +64 9 9235935; fax: +64 9 3737942 (X. Sun), fax: +86 451 53643849 (B. Sun).
    • ,
  • Hongchi Jiang

      Affiliations

    • The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
    • ,
  • Shangha Pan

      Affiliations

    • The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
    • ,
  • Hua Chen

      Affiliations

    • The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
    • ,
  • Shuangjia Wang

      Affiliations

    • The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
    • ,
  • Geoffrey W. Krissansen

      Affiliations

    • Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1005, New Zealand
    • ,
  • Xueying Sun

      Affiliations

    • The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
    • Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1005, New Zealand
    • Corresponding Author InformationCorresponding authors. Address: The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China. Tel.: +64 9 9235935; fax: +64 9 3737942 (X. Sun), fax: +86 451 53643849 (B. Sun).

Received 26 August 2009 ,Revised 4 October 2009 ,Accepted 5 October 2009.

References 

  1. Beger HG, Rau B, Gansauge F, Poch B, Link KH. Treatment of pancreatic cancer: challenge of the facts. World J. Surg. 2003;27:1075–1084
  2. Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, et al. Cetuximab plus Gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br. J. Cancer. 2009;100:1032
  3. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group, Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 2007;25:2212–2217
  4. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69:2400–2407
  5. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2’,2’-difluorodeoxycytidine (gemcitabine). Drug Resist. Updat. 2002;5:19–33
  6. Neumann M, Naumann M. Beyond IkappaBs: alternative regulation of NF-κB activity. FASEB J. 2007;21:2642–2654
  7. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, et al. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin. Cancer. Res. 2008;14:8143–8151
  8. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003;22:90–97
  9. Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L, Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int. J. Cancer. 2004;108:181–188
  10. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer. Res. 1999;5:119–127
  11. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer. Int. J. Cancer. 2003;105:735–746
  12. Chandler NM, Canete JJ, Callery MP. Increased expression of NF-κB subunits in human pancreaticcancer cells. J. Surg. Res. 2004;118:9–14
  13. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, et al. Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology. 2002;123:2052–2063
  14. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 2001;107:135–142
  15. Yebra M, Filardo EJ, Bayna EM, Kawahara E, Becker JC, Cheresh DA. Induction of carcinoma cell migration on vitronectin by NF-kappaB-dependent gene expression. Mol. Biol. Cell. 1995;6:841–850
  16. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse ML, Fölsch UR, et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243–3251
  17. Sebens S, Arlt A, Schäfer H. NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res. 2008;177:151–164
  18. Melisi D, Chiao PJ. NF-κB as a target for cancer therapy. Expert. Opin. Ther. Targets. 2007;11:133–144
  19. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005;65:9064–9072
  20. Müerköster S, Arlt A, Witt M, Gehrz A, Haye S, March C, et al. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int. J. Cancer. 2003;104:469–476
  21. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 2007;67:3853–3861
  22. Mamaghani S, Patel S, Hedley DW. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappa B activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC. Cancer. 2009;9:132
  23. Bass BL. Double-stranded RNA as a template for gene silencing. Cell. 2000;101:235–238
  24. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR. Enhanced chemosensitivity to irinotecan by RNA interference mediated down-regulation of the nuclear factor-κB p65 subunit. Clin. Cancer Res. 2004;10:3333–3341
  25. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991;19:2499
  26. Chen H, Sun B, Pan S, Jiang H, Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs. 2009;20:131–140
  27. Ma L, Luo L, Qiao H, Dong X, Pan S, Jiang H, et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J. Hepatol. 2007;46:98–106
  28. Mai Z, Blackburn GL, Zhou JR. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice. Carcinogenesis. 2007;28:1217–1223
  29. Wang D, Wang Z, Tian B, Li X, Li S, Tian Y. Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int. J. Urol. 2008;15:435–441
  30. Chou TC, Talalay P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984;22:27–55
  31. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug. Discov. 2009;8:33–40
  32. Veiby OP, Read MA. Chemoresistance: impact of nuclear factor (NF)-kappaB inhibition by small interfering RNA. Clin. Cancer Res. 2004;10:3262–3264
  33. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell. Signal. 2008;20:581–589
  34. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 1997;57:1634–1637
  35. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG, Korc M. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology. 1998;55:363–369
  36. Yoshizawa J, Takizawa A, Takeuchi O, Hiraku O, Sasaki K, Morimoto Y, et al. Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemother. Pharmacol. 2009;64:1211–1219
  37. Makiyama A, Qin B, Uchino K, Shibata Y, Arita S, Isobe T, et al. Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines. Anticancer Drugs. 2009;20:123–130
  38. Walensky LD. BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ. 2006;13:1339–1350
  39. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275:1129–1132
  40. Casneuf VF, Demetter P, Boterberg T, Delrue L, Peeters M, Damme N Van. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol. Rep. 2009;22:105–113
  41. Liu F, Tan G, Li J, Dong X, Krissansen GW, Sun X. Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci. 2007;98:1381–1387
  42. Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, et al. Antisense hypoxia-inducible factor 1 α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinomas. Cancer Sci. 2008;99:2055–2061
  43. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938–6943
  44. Kuhnel F, Zender L, Paul Y, Tietze MK, Trautwein C, Manns M, et al. NF-κB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 2000;275:6421–6427
  45. Reuther-Madrid JY, Kashatus D, Chen S, Li X, Westwick J, Davis RJ, et al. The p65/RelA subunit of NF-kappaB suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor. Mol. Cell. Biol. 2002;22:8175–8183
  46. Ortis F, Cardozo AK, Crispim D, Störling J, Mandrup-Poulsen T, Eizirik DL. Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappa B activation. Mol. Endocrinol. 2006;20:1867–1879
  47. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG, et al. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J. Biol. Chem. 2001;276:48921–48929
  48. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, et al. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene. 2002;21:6510–6519

PII: S0304-3835(09)00622-3

doi: 10.1016/j.canlet.2009.10.001

Cancer Letters
Volume 291, Issue 1 , Pages 90-98 , 1 May 2010

Article Tools

* Image Usage & Resolution